Abstract Number: PB0492
Meeting: ISTH 2020 Congress
Background: Cancer patients have a four to sevenfold increased risk of developing venous thromboembolism (VTE). Current prediction models for cancer-associated thrombosis (CAT) perform suboptimal.
Aims: To discover novel plasma biomarkers to improve VTE prediction in cancer patients.
Methods: Plasma samples were used from 142 stage III/IV colorectal cancer patients initiating chemotherapy who were included in a multinational, prospective cohort study. The primary outcome was objectively confirmed symptomatic or incidental deep vein thrombosis or pulmonary embolism during a 6-month follow-up period. Quantitative mass-spectrometry-based targeted proteomics with internal standards was used to measure a panel of 269 proteins including most coagulation and fibrinolysis proteins. The Mann-Whitney U test was performed to compare groups.
Results: Of the 142 patients, 12 (8.5%) developed CAT. Multiplexed targeted proteomics allowed for quantification of 114 peptides in plasma in the qualitative analysis. 38 peptides were measured below the quantitative range in at least in 1 sample, and were therefore excluded from the quantitative analysis. Four proteins were upregulated in patients who developed VTE compared to patients who did not: angiotensinogen (525.2 nM vs. 388.0 nM), apolipoprotein B100 (272.5 nM vs. 202.9 nM), CD5 antigen-like (326.2 nM vs 248.4 nM) and immunoglobulin heavy constant mu, detected by two different peptides (4132.2 nM vs. 2915.6 nM for peptide GFPSVLR and 4143.2 nM vs. 2906.4 nM for peptide VSVFVPPR).
Conclusions: This study identified four plasma proteins that associate with the development of CAT in patients with advanced CRC. Upon validation in an independent cohort, these biomarker candidates may be incorporated in risk models to improve CAT prediction. This could allow for identification of cancer patients who benefit most from thromboprophylaxis.
To cite this abstract in AMA style:Buijs JT, van Es N, Anijs RJS, Bosch FTM, Mulder FI, Versteeg HH, Mohammed Y. Quantitative Mass-Spectrometry-Based Targeted Proteomics of Plasma from Colorectal Cancer Patients with Venous Thromboembolism [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/quantitative-mass-spectrometry-based-targeted-proteomics-of-plasma-from-colorectal-cancer-patients-with-venous-thromboembolism/. Accessed November 27, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/quantitative-mass-spectrometry-based-targeted-proteomics-of-plasma-from-colorectal-cancer-patients-with-venous-thromboembolism/